Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series
- 14-11-2019
- Brief Report
- Auteurs
- Robyn P. Thom
- Christopher J. Keary
- Jessica L. Waxler
- Barbara R. Pober
- Christopher J. McDougle
- Gepubliceerd in
- Journal of Autism and Developmental Disorders | Uitgave 2/2020
Abstract
Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone’s generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.
- Titel
- Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series
- Auteurs
-
Robyn P. Thom
Christopher J. Keary
Jessica L. Waxler
Barbara R. Pober
Christopher J. McDougle
- Publicatiedatum
- 14-11-2019
- Uitgeverij
- Springer US
- Gepubliceerd in
-
Journal of Autism and Developmental Disorders / Uitgave 2/2020
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432 - DOI
- https://doi.org/10.1007/s10803-019-04301-9
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.